Search Results - "Opdam, F. L."

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update by Henricks, L.M., Opdam, F.L., Beijnen, J.H., Cats, A., Schellens, J H M

“…The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine, are frequently prescribed for several types of cancer, including…”
Get full text

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels by Opdam, F. L., Dezentje, V. O., den Hartigh, J., Modak, A. S., Vree, R., Batman, E., Smorenburg, C. H., Nortier, J. W. R., Gelderblom, H., Guchelaar, H.-J.

“…Purpose Adjuvant therapy with tamoxifen significantly reduces breast cancer recurrence and mortality in estrogen receptor positive disease. CYP2D6 is the main…”
Get full text

Failing hormones by OPDAM, F. L, BALLIEUX, B. E. P. B, GUCHELAAR, H, PEREIRA, A. M

Get full text

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects by Dezentjé, V. O., Opdam, F. L., Gelderblom, H., Hartigh den, J., Van der Straaten, T., Vree, R., Maartense, E., Smorenburg, C. H., Putter, H., Dieudonné, A. S., Neven, P., Van de Velde, C. J. H., Nortier, J. W. R., Guchelaar, H.-J.

“…Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels may benefit less from tamoxifen treatment. CYP2D6 poor and…”
Get full text

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands by Kwakman, Johannes J. M., Vink, G., Vestjens, J. H., Beerepoot, L. V., de Groot, J. W., Jansen, R. L., Opdam, F. L., Boot, H., Creemers, G. J., van Rooijen, J. M., Los, M., Vulink, A. J. E., Schut, H., van Meerten, E., Baars, A., Hamberg, P., Kapiteijn, E., Sommeijer, D. W., Punt, C. J. A., Koopman, M.

“…Background The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the…”
Get full text

CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study by Opdam, F. L., Modak, A. S., Mooijaart, S. P., Louwerens, M., de Waal, M. W. M., Gelderblom, H., Guchelaar, H.-J.

“…Background Frailty is a clinical phenotype that is associated with adverse health outcomes. Since frail patients may be more prone for adverse drug events and…”
Get full text

Cerebrovascular events during nilotinib treatment by Jager, N G L, Stuurman, F E, Baars, J W, Opdam, F L

Get full text

The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients by Degreef, L.E, Opdam, F.L, Teepe-Twiss, I.M, Jukema, J.W, Guchelaar, H.J, Tamsma, J.T

“…Abstract Background/aim Statin intolerance is increasingly recognized as a therapy limiting factor in the primary and secondary prevention of cardiovascular…”
Get full text

Molecular Characterization of 3-Phosphoglycerate Dehydrogenase Deficiency—a Neurometabolic Disorder Associated with Reduced L-Serine Biosynthesis by Klomp, Leo W.J., de Koning, Tom J., Malingré, Helga E.M., van Beurden, Ellen A.C.M., Brink, Miny, Opdam, Frans L., Duran, Marinus, Jaeken, Jaak, Pineda, Merce, van Maldergem, Lionel, Poll-The, Bwee Tien, van den Berg, Inge E.T., Berger, Ruud

“…3-phosphoglycerate dehydrogenase (PHGDH) deficiency is a disorder of L-serine biosynthesis that is characterized by congenital microcephaly, psychomotor…”
Get full text

473PPhase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer by Huijberts, S C F A, van Brummelen, E, van Geel, R, Opdam, F L, Marchetti, S, Steeghs, N, Pulleman, S, Thijssen, B, Rosing, H, Monkhorst, K, Huitema, A D R, Beijnen, J H, Bernards, R, Schellens, J H M

“…Abstract Background KRAS oncogene mutations are causing sustained signaling through the mitogen-activated protein kinase (MAPK) pathway resulting in…”
Get full text

438OMETEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours by Siu, L L, Rasco, D W, Vinay, S Postel, Romano, P Martin, Menis, J, Opdam, F L, Heinhuis, K M, Egger, J L, Gorman, S A, Parasrampuria, R, Wang, K, Kremer, B E, Gounder, M M

“…Abstract Background PRMT5 is an enzyme that methylates arginines in proteins important for tumor growth and development. GSK3326595 is a potent and selective…”
Get full text

Further characterization of a ¹³C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy by Opdam, F L, Modak, A S, Gelderblom, H, Guchelaar, H J

“…In a previous study, we found that the CYP2D6 phenotype determined by (13)C-dextromethorphan breath test (DM-BT) might be used to predict tamoxifen treatment…”
Get more information

Erratum to: The use of the ^sup 13^C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels by Opdam, F L, Dezentje, V O, Den Hartigh, J, Modak, A S, Vree, R, Batman, E, Smorenburg, C H, Nortier, J W; R, Gelderblom, H, Guchelaar, H-j

Get full text

The use of the ^sup 13^C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels by Opdam, F L, Dezentje, V O, Den Hartigh, J, Modak, A S, Vree, R, Batman, E, Smorenburg, C H, Nortier, J W; R, Gelderblom, H, Guchelaar, H-j

“…Adjuvant therapy with tamoxifen significantly reduces breast cancer recurrence and mortality in estrogen receptor positive disease. CYP2D6 is the main enzyme…”
Get full text

Erratum to: The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels by Opdam, F. L., Dezentje, V. O., den Hartigh, J., Modak, A. S., Vree, R., Batman, E., Smorenburg, C. H., Nortier, J. W. R., Gelderblom, H., Guchelaar, H.-J.

Get full text